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Introduction
Suppression of bone marrow is frequently 
occurred in patients with cancer due to its 
disease as well as an effect of chemotherapy, 
resulting in a decrease of red cells, leucocytes, 
and platelets. The primary management of 
low red cells and platelet counts or anemia 
and thrombocytopenia, respectively, is 
blood transfusion which is an essential 
component of supportive management.1 
Generally, transfusion tends to be safe and 
has many benefits, however, there is still a 
risk and complication known as transfusion 
reactions.1 These reactions vary from mild 
to life-threatening. Reactions can occur 
during transfusion (acute reactions) or 
in days, even weeks, after the transfusion 
(delayed reactions).2 Several factors that 
affect transfusion reactions, among others 
the patient comorbidity.3 Due to a decrease 
of immunity, patient with cancer tends to 
suffer from transfusion reactions.4 Moreover, 
discrepancy on blood cell antigen5 is also 
related to a higher risk of reaction from a 
blood transfusion.3
The recommendation of blood transfusion 
to patients with cancer is a modification 
component of packed red cells or thrombocyte 
concentrate of which the leukocyte component 
has been reduced and irradiated.6 However, 
some places still use conventional packed red 
cells and thrombocyte concentrate that might 
increase the risk of transfusion reactions.6 
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Abstract
Background: Transfusion is an essential component of supportive management for cancer patients 
with anemia and thrombocytopenia. It is generally safe; however, it has several risks and complications 
including those caused by transfusion reactions. This study aimed to describe transfusion reactions in 
pediatric cancer patients in a tertiary hospital in Indonesia.
Methods: This was a descriptive cross-sectional study with a total sampling method. A prospective 
analysis was performed on episodes of blood transfusion in pediatric patients aged younger than 18 
years old with cancer and were hospitalized at the Department of Child Health of the hospital from July 
to August 2019. After the consent of the parents, the patients were interviewed for various transfusion 
reactions. Data collected were presented using tables and charts. 
Results: Leukemia was the most frequent cancer in children cancer patients who need transfusion. 
Out of 42 children included, 155 episodes of transfusion were observed with 22 episodes showed 
transfusion reactions (14.2%). The most frequent manifestations were pruritus (31.8%), followed by 
combination of pruritus and erythema (27.4%) and fever (13.6%). These reactions appeared mostly in 
1 to 2 hours (27.2%), with most were mild reactions (59.1%).
Conclusions: Transfusion reactions mostly occur among pediatric patients with cancer in the acute 
phase with clinical manifestation of allergic reactions, predominantly mild. Early identification of these 
reactions will result in better treatment and prevention for recurrence of transfusion reactions.
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Data on transfusion reactions among pediatric 
cancer patients at Dr. Hasan Sadikin General 
Hospital Bandung as a referral hospital in 
West Java is still limited. Therefore, the study 
on transfusion reactions among pediatric 
patients with cancer was explored. 
Methods
This study design was a cross-sectional study 
with a descriptive approach. The technique of 
data collection was the total sampling method. 
A prospective analysis was performed on all 
pediatric patients aged younger than 18 years 
old that were diagnosed with cancer and 
hospitalized at Dr. Hasan Sadikin Bandung 
General Hospital from July to August 2019.
Data about reaction transfusion was 
collected by using a standardized closed 
question interview method based on the 
form of transfusion reaction report from the 
Department of Clinical Pathology Dr. Hasan 
Sadikin Bandung General Hospital. Data 
were analyzed according to their transfusion 
episode established, based on the transfusion 
time and blood component. The exclusion 
criteria were the patient who did not fill in the 
questionnaire. The data was taken daily, for 
Table 1 Clinical Characteristic of Pediatrics Patients with Cancer Undergone Blood 





     0–<5 years old 10 23.8
     5–<10 years old 13 31.0
     10–18 years old 19 45.2
Gender
     Male 19 54.8
     Female 23 45.2
Blood type
     A 15 35.7
     B 8 19.0
     AB 6 14.3
     O 13 31.0
     Rhesus + 41 97.6
     Rhesus - 1 2.4
Clinical Diagnosis
     Acute Leukemia 1 2.4
     Acute Myeloblastic Leukemia 7 16.7
     Acute Lymphoblastic Leukemia 22 52.4
     Chronic Myeloblastic Leukemia 1 2.4
     Neuroblastoma 2 4.8
     Retinoblastoma 2 4.8
     Osteosarcoma 5 11.9
     Non Hodgkin’s Cancer Lymphoma 1 2.4
     Hodgkin’ Cancer Lymphoma 1 2.4
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30 consecutive days at a time. After informed 
consent to the parents, the interview was 
conducted with both parents and patients. 
The patient aged older than 12 years old was 
interviewed using the auto anamnesis method, 
and for patients aged younger than 12 years 
old using alloanamnesis method. The data 
that was gathered then reviewed in the form 
of blood transfusion monitoring data that was 
recorded in the medical record of the patient. 
This study was approved by The Research 
Ethics Committee of Universitas Padjajaran 
no. 120/UL6.KP/ET/2019 and permission 
was given by The Medical Research Ethics 
Committee of Dr. Hasan Sadikin General 
Hospital Bandung no. LB/X.3/102/2018. 
Variables of this study were patient identity 
(age, sex, blood type, and clinical diagnosis), 
transfusion episode (blood components), and 
transfusion reactions (clinical manifestation 
and onset). The data were analyzed using 
descriptive statistics and processed by using 
Microsoft® Excel 2016 and IBM® SPSS® 
version 22. The data was then presented in 
the form of a table, percentage, and chart to 
draw patient identity, transfusion episodes, 
and transfusion reactions.
Results
In total, data on 42 patients with one 
hundred fifty-five episodes of transfusion 
were collected. Blood transfusion was mostly 
given to males (54.8%). About half of the 
patients (45.2%) were in the age group 10 
to 18 years old. The most blood type in this 
study was blood type A (35.7%) and rhesus 
(+) (97.6%). The clinical diagnosis was acute 




Packed Red Cells Thrombocyte Concentrate
N % N % N %
Fever, pruritus, and erythema 1 4.5 1 4.5 2 9.1
Pruritus and erythema 4 18.3 2 9.1 6 27.4
Fever and shortness of breath 1 4.5 - - 1 4.5
Pruritus 3 13.5 4 18.3 7 31.8
Shortness of breath 1 4.5 - - 1 4.5
Fever 2 9.1 1 4.5 3 13.6
Shivering - - 1 4.5 1 4.5
Back Pain - - 1 4.5 1 4.5





N % N % N %
Fever, pruritus, and erythema 2 9.1 0 0 2 9.1
Pruritus and erythema 4 18.3 2 9.1 6 27.4
Fever and shortness of breath 1 4.5 - - 1 4.5
Pruritus 5 22.7 2 9.1 7 31.8
Shortness of breath 1 4.5 - - 1 4.5
Fever 3 13.6 - - 3 13.6
Shivering 1 4.5 - - 1 4.5
Back Pain - - 1 4.5 1 4.5
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leukemia lymphoblastic (52.4%), followed 
by acute myeloblastic leukemia (16.7%). Of 
155 transfusion episodes, 22 episodes had 
transfusion reactions (14.2%) experienced by 
thirteen patients of whom two patients had 
repeated reactions.
Thrombocyte concentrate was frequently 
used in transfusion (54.2%), followed 
by packed red cells (45.8%). The clinical 
manifestations due to transfusion reactions 
were pruritus (31.8%), followed by both 
pruritus and erythema (27.4%) and fever 
(13.6%). While investigating the reactions 
based on blood components, packed red cell 
was the component that was more related to 
transfusion reactions (54.4%) as shown in 
table 2. Furthermore, leukemia was the most 
manifestation related to transfusion reactions 
(Table 3).
Based on the onset, most of the transfusion 
reactions occurred within 1 to 2 hours after 
starting transfusion (27.2%) as depicted in 
Table 4. In this acute transfusion reaction, 
59.1% experienced a mild reaction.
Discussions
This study has reported that the age group of 
10 to 18 years and male are predominantly 
given a blood transfusion, similar to the study 
from Brazil.7 Based on epidemiological studies, 
cancer occurring between the ages of 15 and 
30 years is 2.7 times more common than 
cancer occurring during the first 15 years of 
life.8 Susceptibility to cancer is generally higher 
in males, although some cancers are more 
common in women.9 Lymphoblastic leukemia 
acute is a type of cancer that frequently needs 
a transfusion.7 Leukemia is one of the most 
prevalent cancers in Indonesia.
Of 155 transfusion episodes, transfusion 
reactions have been reported in 22 episodes 
(14.2%). Leukemia requires transfusion 
intensively and this cancer is the most 
cancer related to repeated transfusion 
reactions. Repeated blood transfusions 
might be associated with the production of 
alloantibodies against one or more antigens, 
which complicate subsequent transfusions, 
including the increased risk of delayed 
transfusion reactions.10 Furthermore, repeated 
transfusion reactions are also associated with 
patient comorbidity.3
Interestingly, the number of transfusion 
reactions in our study is relatively higher 
compared with the study conducted in 
Brazil that reported transfusion reactions of 
1.13%.11 Generally, a patient with cancer is 
immune suppressed, leading to an increase 
in transfusion reaction risks.4 One of the 
reasons is the inability of the immune system 
to reject antigen received during transfusion, 
due to immunodeficiency states of B and T 
lymphocytes. Patients with cancer may have 
an undetected immunoglobulins level that 
causes the presence of discrepancy in blood 
cell antigen.5 Moreover, aside from cancer 
itself, the use of blood components affects 
transfusion reactions as well.12
The study in blood bank hospital has 
established a protocol that patients with 
cancer should be given leuco-depleted blood 




     0–15 minutes 1 4.5
     >15–30 minutes 4 18.3
     >30 minutes–1 hour 3 13.7
     >1–2 hours 6 27.2
     >2–3 hours 3 13.7
     >3 hr 5 22.6
Type of acute transfusion reaction
     Mild 13 59.1
     Moderate-severe 7 31.8
     Life-threatening 2 9.1
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components.7 In contrast, most of the blood 
components for blood transfusion given 
to patients in this study are thrombocyte 
concentrate and followed by packed red cells; 
no leuco-depleted blood component. Packed 
red cells and thrombocytes can contain 
leukocytes, higher than the leuco-depleted 
blood component.13 This affects the component 
containing human leukocyte antigen (HLA) 
and proinflammatory cytokines such as IL-
1β, IL-6, IL-8, and TNF that are relatively high 
and can increase the incidents of transfusion 
reactions, especially non-hemolytic reactions.6 
The use of leuco-depleted blood component is 
more effective to reduce the risk of transfusion 
reactions.12
Furthermore, our study has shown that 
most of the transfusion reactions have been 
recorded in the acute phase (>24 hours) with 
most patients experienced mild reactions. 
Interestingly, transfusion reactions can occur 
in a shorter onset, which is within the first 
hour,14 or even in 15 minutes after starting 
transfusion.1 Taken together, the transfusion 
reactions are acute and not delayed. One 
possibility is an increased Th2 and decreased 
Th1 profile that is related to an increase 
risk of hypersensitivity.15 IgE recipients may 
react to the donor of plasma protein that 
tends to release mast cell mediators.16 This 
phenomenon also explains that the clinical 
manifestation of pruritus appeared the most. 
Similar to the study in Brazil, exposed allergic 
reactions is transfusion reactions that are 
generally occurring within pediatric patients 
with cancer.3 However, a fever could be the most 
frequent transfusion reaction as opposed in a 
study from Uganda.11 Interestingly, the number 
of pruritus incidents is high, suggesting as one 
of the allergic manifestations (31.8%) shows 
in a relationship of patients’ age on transfusion 
reactions. The children aged 1 to 2 years old 
tend to be more susceptible to nonhemolytic 
transfusion reactions, whereas those older 
than 2 years are prone to experience allergic 
reactions, nevertheless, it may be required 
further study.3
This study has limitations among others 
that the transfusion reactions result is not from 
observation but interview. The data might give 
a recall bias. A good clinical observation is the 
need for further study. 
To conclude, transfusion reactions 
in children with cancer mostly occur in 
leukemia with frequent allergic reactions 
as clinical manifestation. The onset is acute 
with most experienced as a mild reaction. 
Since the occurrence of transfusion reactions 
in children with cancer is relatively higher 
than total transfusion reactions at Dr. Hasan 
Sadikin General Hospital, it requires an effort 
to decrease and prevent repeated transfusion 
reactions by utilizing the leukocyte-reduction 
technology and gamma irradiation. The form 
for transfusion reactions needs to be improved 
as monitoring and evaluation of the occurrence 
of transfusion reaction.
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